Ocugen, Inc. - צמיחת הכנסות שנתית ב-12 החודשים האחרונים OCGN

Ocugen, Inc. relies entirely on outsourcing its development and production to external contractors. The TTM revenue growth rate compared to last year shows that the parameter is -10.90. Meanwhile, patent protection and strict regulatory oversight create significant barriers to entry. However, the risk of funding shortages and the necessity of secondary offerings to finance gene therapy remain pertinent.
פילוחי נתונים אנליטיים מרוכזים עבור Ocugen Corp (OCGN)

For Ocugen, Inc. (OCGN), the annual change in sales volume over the LTM reflects the commercialization rates of gene therapies and vaccines through government procurement and insurance reimbursements. This indicator captures revenue dynamics over the last twelve months relative to the same period last year, allowing investors to assess the sustainability of business expansion and the risk of overpaying for the asset at the peak of the cycle.